Post-infectious irritable bowel syndrome

被引：151

作者：

Thabane, Marroon ^{[2
]}

Marshall, John K. ^{[1
]}

机构：

[1] McMaster Univ, Div Gastroenterol, Med Ctr, Hamilton, ON L8N 3Z5, Canada

[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2009年 / 15卷 / 29期

关键词：

Irritable bowel syndrome; Functional colonic disease; Gastroenteritis; Functional bowel disorder; PLACEBO-CONTROLLED TRIAL; FUNCTIONAL GASTROINTESTINAL DISORDERS; ENTEROCHROMAFFIN CELL HYPERPLASIA; INTESTINAL BACTERIAL OVERGROWTH; WATERBORNE GASTROENTERITIS GE; RANDOMIZED CONTROLLED-TRIAL; DIARRHEA-PREDOMINANT IBS; DOUBLE-BLIND; RECEPTOR ANTAGONIST; WALKERTON OUTBREAK;

D O I：

10.3748/wjg.15.3591

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Post-infectious irritable bowel syndrome (PI-IBS) is a common disorder wherein symptoms of IBS begin after an episode of acute gastroenteritis. Published studies have reported incidence of PI-IBS to range between 5% and 32%. The mechanisms underlying the development of PI-IBS are not fully understood, but are believed to include persistent sub-clinical inflammation, changes in intestinal permeability and alteration of gut flora. Individual studies have suggested that risk factors for PI-IBS include patients' demographics, psychological disorders and the severity of enteric illness. However, PI-IBS remains a diagnosis of exclusion with no specific disease markers and, to date, no definitive therapy exists. The prognosis of PI-IBS appears favorable with spontaneous and gradual resolution of symptoms in most patients. (C) 2009 The WJG Press and Baishideng. All rights reserved.

引用

页码：3591 / 3596

页数：6

共 75 条

[1]

Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea:: A crossover, randomized trial [J].

Attar, A ;

Flourié, B ;

Rambaud, JC ;

Franchisseur, C ;

Ruszniewski, P ;

Bouhnik, Y .

GASTROENTEROLOGY, 1999, 117 (04) :794-797

[2]

Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice [J].

Barbara, G ;

De Giorgio, R ;

Deng, YK ;

Vallance, B ;

Blennerhassett, P ;

Collins, SM .

GASTROENTEROLOGY, 2001, 120 (07) :1729-1736

[3]

Bardhan KD, 2000, ALIMENT PHARM THERAP, V14, P23

[4]

The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection [J].

Borgaonkar, Mark R. ;

Ford, David C. ;

Marshall, John K. ;

Churchill, Elizabeth ;

Collins, Stephen M. .

DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (05) :1026-1032

[5]

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial [J].

Camilleri, M ;

Northcutt, AR ;

Kong, S ;

Dukes, GE ;

McSorley, D ;

Mangel, AW .

LANCET, 2000, 355 (9209) :1035-1040

[6]

Probiotics and irritable bowel syndrome: Rationale, putative mechanisms, and evidence of clinical efficacy [J].

Camilleri, M .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2006, 40 (03) :264-269

[7]

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome [J].

Camilleri, M ;

Chey, WY ;

Mayer, EA ;

Northcutt, AR ;

Heath, A ;

Dukes, GE ;

McSorley, D ;

Mangel, AM .

ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (14) :1733-1740

[8]

Camilleri M, 1999, ALIMENT PHARM THERAP, V13, P1149

[9]

Probiotics and irritable bowel syndrome [J].

Camilleri, Michael .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (08) :S123-S125

[10]

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS [J].

Chang, L ;

Ameen, VZ ;

Dukes, GE ;

McSorley, DJ ;

Carter, EG ;

Mayer, EA .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (01) :115-123

← 1 2 3 4 5 6 7 8 →